Using ligands to target cancer cells

Clinical Advances in Hematology and Oncology

Volumn 10, Issue 8, 2012, Pages 543-545

  Farokhzad, Omid C ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIND 014; DOCETAXEL; NANOCARRIER; NANOPARTICLE; PROSTATE SPECIFIC MEMBRANE ANTIGEN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANUS CANCER; ARTICLE; BILE DUCT CANCER; CANCER CELL; COLORECTAL CANCER; CONTROLLED DRUG RELEASE; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; GENE THERAPY; HUMAN; MACROPHAGE; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; RNA INTERFERENCE; TONSIL CANCER; UTERINE CERVIX CANCER;

ANTIGENS, SURFACE; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; DRUG CARRIERS; DRUG COMPOUNDING; ENDOTHELIAL CELLS; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; LAB-ON-A-CHIP DEVICES; LIGANDS; MALE; NANOMEDICINE; NANOPARTICLES; PROSTATIC NEOPLASMS; RNA INTERFERENCE; TAXOIDS;

EID: 84868270139     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. www.ClinicalTrials.Gov. A phase I, open label, safety, pharmacokinetic and pharmacodynamic dose escalation study of BIND-014 given by IV infusion to patients with advanced or metastatic cancer. http://clinicaltrials.gov/ct2/show/NCT01300533. Identifer: NCT01300533. Accessed July 17, 2012.
2. Summa J, LoRusso PM, Eisenberg P, et al. Abstract LB-452: a phase I, open label, safety, pharmacokinetic and pharmacodynamic dose escalation study of BIND-014 given by IV infusion to patients with advanced or metastatic cancer. Cancer Res (AACR Annual Meeting Abstracts). 2012;72(8 suppl): Abstract LB-452.
3. Kamaly N, Xiao Z, Valencia PM, Radovic-Moreno AF, Farokhzad OC. Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev. 2012;41:2971-3010.
4. Xiao Z, Levy-Nissenbaum E, Alexis F, et al. Engineering of targeted nanoparticles for cancer therapy using internalizing aptamers isolated by cell-uptake selection. ACS Nano. 2012;24;6:696-704.
5. Karve S, Werner ME, Sukumar R, et al. Revival of the abandoned therapeutic wortmannin by nanoparticle drug delivery. Proc Natl Acad Sci U S A. 2012;109:8230-8235.
6. Shi J, Votruba AR, Farokhzad OC, Langer R. Nanotechnology in drug delivery and tissue engineering: from discovery to applications. Nano Lett. 2010;10:3223-3230.
7. Hrkach J, Von Hof D, Mukkaram Ali M, et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a diferentiated pharmacological profle. Sci Transl Med. 2012;4:128ra39.
8. Heath TD, Fraley RT, Papahdjopoulos D. Antibody targeting of liposomes: cell specifcity obtained by conjugation of F(ab')2 to vesicle surface. Science. 1980;210:539-541.